PRINCETON - Grace Therapeutics, Inc. (NASDAQ:GRCE), a clinical-stage biotech company with a market capitalization of $43 million and strong liquidity position according to InvestingPro data, presented ...
Grace Therapeutics, Inc. has announced positive results from its Phase 3 STRIVE-ON trial for GTx-104, an injectable formulation of nimodipine aimed at treating aneurysmal Subarachnoid Hemorrhage (aSAH ...
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE), formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late ...
PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE)-- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, ...
Grace Therapeutics' lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results